CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock

John Carroll

Editor & Founder

Mitch Gold’s plans to push the envelope on cell therapy 2.0 has crashed into a fresh safety issue — and this time his biotech is ready to call it quits on the lead in-house effort.

Seven months after Alpine Immune Sciences’ davoceticept (ALPN-202) was sidelined by regulators after the death of a patient from cardiogenic shock, the biotech is back with fresh news of another death — also by cardiogenic shock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

House Oversight chair presses FDA on China amid growing tensions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients

CD28 kills again? Mitch Gold’s plan to make cell ther­a­py 2.0 his­to­ry crash­es af­ter an­oth­er pa­tient dies of car­dio­genic shock

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

House Over­sight chair press­es FDA on Chi­na amid grow­ing ten­sions

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

House Oversight chair presses FDA on China amid growing tensions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients